Jeffrey Tyner
Papers
1
Total Citations
2
H-Index
1
About
Dr. Jeffrey Tyner is a leading cancer researcher whose work focuses on functional precision oncology, particularly in acute leukemias. He is renowned for pioneering the use of ex vivo drug sensitivity profiling to match patients with targeted therapies, a paradigm-shifting approach that moves beyond genomic sequencing alone. His most impactful contributions include identifying the exceptional sensitivity of TCF3-HLF rearranged acute lymphoblastic leukemia (ALL) to Aurora kinase inhibition, a finding that offers a lifeline for a subtype with a historically dismal prognosis. This work, published in 2018, has garnered significant attention and is driving clinical trials. With over 100 publications and thousands of citations, Dr. Tyner’s research has directly influenced treatment strategies for relapsed and refractory leukemias. He has been recognized with multiple awards, including the St. Baldrick’s Foundation Scholar Award, and his leadership in the Beat AML Master Trial exemplifies his commitment to translating laboratory discoveries into actionable, patient-specific therapies.
Research Focus
Key Achievements
Top Papers
- 1